Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock plunged on Monday as the company navigates recent developments in its clinical trials.
On Monday, Roche Holdings AG (OTC:RHHBY) released data from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients.
The study did not meet its primary objective of a statistically significant improvement in progression-free survival versus letrozole plus palbociclib.
The study showed a numerical improvement.
Roche’s Giredestrant is an investigational, oral, potent next-generation selective oestrogen receptor degrader (SERD) and full antagonist.
Olema Pharmaceuticals‘ Palazestrant Clinical Trial Update
Olema’s lead product candidate, Palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and SERD.
The stock is experiencing bullish momentum following updates on its lead product candidate, Palazestrant, which is undergoing various clinical trials for breast cancer.
In November 2025, Olema Pharmaceuticals surged over 200% after Roche released phase 3 results from the lidERA Breast Cancer study of giredestrant in early-stage breast cancer.
OLMA’s Bearish Technical Indicators
The stock is currently trading 26.2% below its 20-day SMA and 19% below its 100-day SMA, indicating a bearish trend in the short to medium term.
Shares have increased by 294.05% over the past 12 months and are currently positioned closer to their 52-week lows than highs.
The RSI is at 34.36, which is considered neutral territory, while the MACD is at -0.6379, below its signal line, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum, reflecting uncertainty in the stock’s near-term outlook.
- Key Resistance: $22.50
- Key Support: $13.50
OLMA’s Premarket Price Movement
OLMA Price Action: Olema Pharmaceuticals shares were down 2.54% at $15.36 at the time of publication on Wednesday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments